The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
This session will cover a wide range of topics from cell therapies, like CAR-T cells, to new cell-derived therapies. We will develop the understanding mechanisms and research in this session, including the clinic with feedback from international speakers (Austria, China, Germany, …). Transfers in clinical development will also be discussed.
Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of cell and gene therapies in France and worldwide to propose these innovative drugs to patients.
This session will highlight the capacity of the University Hospital Center to conduct clinical trials and what issues to anticipate. On this occasion, we will give examples from the regional ecosystem with pre-industrial structures.
We will also talk about the regulatory science and innovation task force by the European Medicines Agency and the guidelines defined for ATMPs in European and America.
17 :00 – 21 :00 : Visit of Bio Innovation and friendly welcome reception
Presentation of the regional eco-system
8:30-09:00 : REGISTRATION AND WELCOME COFFEE (KURSAAL BALLROOM)
9:00-09:25 : WELCOME ADRESS AND INTRODUCTION (KURSAAL CONF ROOM)
Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR
Welcome words from the urban community’s President and the Region’s President
9:25-12:30 : CAR-T CELLS (KURSAAL CONF ROOM)
Chairmen : Dr Christophe Ferrand and Dr Marina Deschamps, RIGHT institute, Besançon, FR
09:25 : High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Peihua (Peggy) Lu, MD, Lu Daopei Hospital and Beijing Lu Daopei Institute of Hematology, China
09:55 : Enabling manufacturing of gene-editing cell therapies
Dr Mélanie Rietenbach, Miltenyi Biotech, Düsseldorf, Germany
10:25 : Small talk
xx, xx, xx
10:30 : BREAK – EXHIBITION HALL
11:00 : UPCOMING TITLE
xx, xx, xx
11:30 : Allogeneic CAR T-cells for Adoptive Cell Therapy
Dr Roman Galetto, Cellectis, Paris, France
12:00 : Identification of molecular mechanisms governing CAR-T cell response using single cell transcriptomics
Dr Juan R. Rodriguez-Madoz, Center for Applied Medical Research (CIMA), University of Navarra, Spain
12:30 : Small talk
xx, xx
12:35-14:00 : LUNCH (KURSAAL BALLROOM)
13:30-15:00 : Exhibition Hall – B2B MEETINGS
14:15-15:00 : SYMPOSIUM – INSTITUT RIGHT (KURSAAL CONF ROOM)
15:00-18:30 : UPCOMING INNOVATIVE THERAPIES (KURSAAL CONF ROOM)
Chairmen :XX, xx and Dr Sylvain Perruche, RIGHT Institute, Besançon, FR
15:00 : UPCOMING TITLE
Philippe Gruet, Vetoquinol, Lure, France
15:30 : Upcoming Title
XX, xx
16:00 : SECRETOME FROM PERIPHERAL WHITE BLOOD CELLS (PBMCS) DRIVEN INTO APOPTOSIS FOR TISSUE REPAIR – TITLE TO BE ANNOUNCED
Prof. Dr. Hendrik Ankersmit, Medical University of Vienna and Aposcience, Vienne, Austria
16:30 : Small talk
16:35 : BREAK – EXHIBITION HALL
17:00 : UPCOMING TITLE
xx, xx, xx
17:30 : CELLS OR SECRETOME FOR TREATMENT OF HEART FAILURE
Prof. Dr. Philippe Menasché, Department of Cardiovascular Surgery and INSERM U970 – Hôpital Européen Georges Pompidou, Paris, France
18:00-19:00 : B2B MEETINGS
19:00-20:00 : COCKTAIL
20:00-23:30 : EVENING RECEPTION (KURSAAL BALLROOM)
(KURSAAL CONF ROOM)
Chairmen: XX xx
09:00 : Regulatory Science and Innovation Task Force, Title to be announced
Dr Oriane Blanquie, European Medicines Agency, Amsterdam, Netherlands
09:30 : UPCOMING TITLE
XX, xx, xx
10:00 : BREAK- EXHIBITION HALL
10:30 : UPCOMING TITLE
Pr Eric Toussirot, Besançon University Hospital, Besançon, France
11:00 : UPCOMING TITLE
xx, xx, xx
11:30 : UPCOMING TITLE
Dr Jérémy Magalon, AP-HM, Marseille, France
12:00-14:00 : LUNCH (KURSAAL BALLROOM)
12:40-14:00 : Exhibition Hall – B2B MEETINGS
14:00-16:30 : CELL THERAPIES (KURSAAL CONF ROOM)
Chairmen : xx and xx
14:00 : UPCOMING TITLE
xx, xx, xx
14:30 : Human CD34+ cells for the treatment of acute ischemic stroke
Dr. Ibon Garitaonandia, CellProthera, Mulhouse, France
15:00 : BREAK- EXHIBITION HALL
15:30 :UPCOMING TITLE
xx, xx, xx
16:00 : UPCOMING TITLE
xx, xx, xx
16:30-CONCLUSION END OF CONGRESS
16:45 – BEER PARTY AND/OR B2B MEETNGS ?
Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Dr Mathieu GUERRIAUD – CREDIMI (Dijon, FR), Sylvain PERRUCHE – RIGHT Institute (Besançon, FR), Dr Peihua (Peggy) LU – Lu Daopei Hospital & Institute of Hematology (Beijing, RPC), Dr Melanie RIETENBACH – Miltenyi Biotec ( Düsseldorf, DE), Dr Oriane BLANQUIE, EMA ( Amsterdam, NL)
Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology. Dr. Lu graduated from Peking University Medical School, and had her residency training at the University of Nebraska Medical Center in USA. She completed her hematology and oncology fellowship at Stanford University Medical Center.
En savoir +Dr. Ibon Garitaonandia is the Chief Scientific Officer at CellProthera, a French clinical stage biotechnology company developing stem cell based therapies for cardiovascular and ischemic indications. He is conducting a Phase 2 study in post-acute myocardial infarction (NCT02669810) and preclinical...
En savoir +Dr. Keirstead is an internationally known stem cell expert and serial entrepreneur that led the development of a treatment that restored movement and sensory function to people with quadriplegic spinal cord injury, and a treatment for cancer that has saved...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +Melanie Rietenbach is a Global Product Manager for the Immunotherapy portfolio at Miltenyi Biotec. During the last 3 years, she has been working together with the R&D and Clinical Development Team in order to advance the development of tools to...
En savoir +Dr Philippe Menasché is a cardiac surgeon at the Georges Pompidou European Hospital, Professor of Thoracic and Cardiovascular Surgery at the Paris-Cité University, and is in charge of an INSERM team dedicated to cell therapy for heart failure. After the...
En savoir +After completing my pharmacy studies in Paris, France, I did a PhD in Neuroscience at the University Medical Center of Mainz, Germany (2013-2017), followed by a postdoc at the German Center for Neurodegenerative Diseases in Bonn, Germany (2017 – 2018)....
En savoir +A doctor in biology, the Bisontinental Inserm researcher worked for nearly ten years within Inserm's Joint Research Unit 1098 - hosted by the Etablissement français du sang Bourgogne-Franche-Comté, in Besançon - in the development of therapeutic approaches to control the...
En savoir +Dr. Brandenberger is the Chief Technical Officer and oversees technical operations, including process and analytical development, supply chain, manufacturing, and quality for Nkarta’s engineered NK cell therapy candidates. He has more than 20 years of experience in process and analytical...
En savoir +